Literature DB >> 22056851

Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications.

O Mir, R Coriat, P Boudou-Rouquette, J P Durand, F Goldwasser.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22056851     DOI： 10.1093/annonc/mdr525

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

Review 1.  Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib.

Authors:  Alessandro Granito; Sara Marinelli; Giulia Negrini; Saverio Menetti; Francesca Benevento; Luigi Bolondi
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 2.  Drug-Induced Hypophosphatemia: Current Insights.

Authors:  Efstathia Megapanou; Matilda Florentin; Haralampos Milionis; Moses Elisaf; George Liamis
Journal:  Drug Saf       Date:  2020-03       Impact factor: 5.606

Review 3.  Renal effects of targeted anticancer therapies.

Authors:  Camillo Porta; Laura Cosmai; Maurizio Gallieni; Paolo Pedrazzoli; Fabio Malberti
Journal:  Nat Rev Nephrol       Date:  2015-03-03       Impact factor: 28.314

4.  Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.

Authors:  Jennifer A Chan; Robert J Mayer; Nadine Jackson; Paige Malinowski; Eileen Regan; Matthew H Kulke
Journal:  Cancer Chemother Pharmacol       Date:  2013-03-09       Impact factor: 3.333

5.  Safety and Efficacy of Physical Thermal Ablation Combined Sorafenib for Hepatocellular Carcinoma: A Meta-analysis.

Authors:  Mengdi Jin; Qiong Yu; Yahui Liu; Weiling Xu; Xueqi Fu; Bai Ji
Journal:  J Clin Transl Hepatol       Date:  2021-03-08

6.  Patient-Level Adverse Event Patterns in a Single-Institution Study of the Multi-Kinase Inhibitor Sorafenib.

Authors:  S Karovic; E F Shiuan; S Q Zhang; H Cao; M L Maitland
Journal:  Clin Transl Sci       Date:  2016-07-21       Impact factor: 4.689

7.  Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.

Authors:  Álvaro Díaz-González; Víctor Sapena; Loreto Boix; Ferrán Torres; Marco Sanduzzi-Zamparelli; Leonardo G Da Fonseca; Neus LLarch; Gemma Iserte; Cassia Guedes; Sergio Muñoz-Martínez; Anna Darnell; Ernest Belmonte; Jordi Rimola; Alejandro Forner; Carmen Ayuso; Jordi Bruix; María Reig
Journal:  United European Gastroenterol J       Date:  2021-07-06       Impact factor: 4.623
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.